180 Life Sciences Reports Positive Topline Results Of A Clinical Pharmacology Study Testing A New Solid Formulation Of CBD With Enhanced Oral Uptake; Twelve Volunteers Received All Three Formulations In A Crossover Randomized Trial
Portfolio Pulse from Benzinga Newsdesk
180 Life Sciences Corp. (NASDAQ:ATNF) announced positive topline results from a clinical pharmacology study comparing two solid formulations of CBD with the FDA-approved drug Epidiolex. The study found that one of the solid forms was absorbed faster and exhibited higher maximal levels compared to Epidiolex.
July 30, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
180 Life Sciences Corp. reported positive results from a clinical study comparing two solid formulations of CBD with Epidiolex. One of the solid forms showed faster absorption and higher maximal levels, which could enhance the company's market position in the CBD pharmaceutical space.
The positive results from the clinical study could boost investor confidence in 180 Life Sciences' ability to develop effective CBD formulations, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100